Flag of the European Union EU Clinical Trials Register Help

Clinical trials for PL 1

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    8,459 result(s) found for: PL 1. Displaying page 234 of 423.
    «« First « Previous 230  231  232  233  234  235  236  237  238  Next» Last»»
    EudraCT Number: 2012-001258-25 Sponsor Protocol Number: MK8962-031-00 Start Date*: 2012-11-29
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A phase III, multi-center, open label, uncontrolled trial to investigate the efficacy and safety of MK-8962 (corifollitropin alfa) in combination with human Chorionic Gonadotropin (hCG) in inducing...
    Medical condition: Hypogonadotropic hypogonadism (HH) in males may result from either absent or inadequate gonadotropin-releasing hormone (GnRH) secretion by the hypothalamus or failure of pituitary gonadotropin secr...
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004860 10021012 Hypogonadotrophic hypogonadism LLT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed) ES (Completed) IT (Completed) GB (Completed) PL (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-004058-40 Sponsor Protocol Number: EUDARIO Start Date*: 2018-10-16
    Sponsor Name:Katholieke Universiteit Leuven
    Full Title: A multicentre, open-label, three-arm randomised Phase II trial assessing the safety and efficacy of the HSP90 inhibitor Ganetespib in combination with Carboplatin followed by maintenance treatment ...
    Medical condition: Platinum-sensitive relapsed ovarian cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) DE (Completed) FR (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002676-14 Sponsor Protocol Number: B7921023 Start Date*: 2020-08-26
    Sponsor Name:Pfizer Inc.
    Full Title: A 24-WEEK RANDOMIZED, DOUBLE BLIND, PARALLEL GROUP, ACTIVE COMPARATOR, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF PF 06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN P...
    Medical condition: Rheumatoid arthritis (RA) is a chronic, autoimmune disease characterized by joint inflammation
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) HU (Completed) SK (Completed) CZ (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2021-001086-20 Sponsor Protocol Number: DP-1111-02CT Start Date*: 2021-10-19
    Sponsor Name:ITM Solucin GmbH
    Full Title: A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate Efficacy, Safety and Patient- reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (177Lu...
    Medical condition: Well-differentiated Aggressive Grade2 and Grade 3, Somatostatin receptor-positive (SSTR+), Neuroendocrine Tumors of GastroEnteric or Pancreatic Origin (GEP-NET)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077559 Gastroenteropancreatic neuroendocrine tumour disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-003895-65 Sponsor Protocol Number: DAL-301 Start Date*: 2016-06-22
    Sponsor Name:DalCor Pharma UK Ltd, Leatherhead, Swiss Branch Zug
    Full Title: A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Sy...
    Medical condition: This study is investigating the cardiovascular morbidity and mortality (cardiovascular death, resuscitated cardiac arrest, non-fatal myocardial infarction (MI) and non-fatal stroke) in subjects wit...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10051592 Acute coronary syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) SE (Completed) SK (Completed) DK (Completed) FI (Completed) PT (Completed) DE (Completed) HU (Completed) ES (Ongoing) AT (Completed) CZ (Completed) BG (Completed) RO (Ongoing) PL (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000184-40 Sponsor Protocol Number: 20130173 Start Date*: 2014-09-11
    Sponsor Name:Amgen, Inc.
    Full Title: Prospective, Multicenter, Single-arm Study to Evaluate Efficacy, Safety, and Pharmacokinetics of Denosumab in Children With Osteogenesis Imperfecta
    Medical condition: Osteogenesis Imperfecta
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10031243 Osteogenesis imperfecta PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) GB (GB - no longer in EU/EEA) HU (Completed) ES (Completed) Outside EU/EEA BG (Completed) PL (Prematurely Ended) BE (Completed) FR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-004770-25 Sponsor Protocol Number: D7310C00001 Start Date*: 2020-12-11
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination with Cetuximab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head an...
    Medical condition: Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) GR (Completed) DE (Trial now transitioned) BE (Completed) AT (Completed) BG (Completed) PL (Completed) FR (Completed) PT (Completed) IT (Completed) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001973-25 Sponsor Protocol Number: MK-7339-001 Start Date*: 2018-12-13
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First- Line Treatment of BRCA non-mutated Advanced Ep...
    Medical condition: Advanced epithelial ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) CZ (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) HU (Trial now transitioned) DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002674-31 Sponsor Protocol Number: 73763989PAHPB2002 Start Date*: 2019-12-16
    Sponsor Name:Janssen Sciences Ireland UC
    Full Title: A Randomized, Double blind, Placebo-controlled Phase 2b Study to Evaluate Efficacy, Pharmacokinetics, and Safety of 48-week Study Intervention With JNJ-73763989+JNJ-56136379+Nucleos(t)ide Analog (N...
    Medical condition: Chronic Hepatitis B Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10008910 Chronic hepatitis B PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) FR (Completed) PL (Completed) ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-003343-29 Sponsor Protocol Number: ACP-103-064 Start Date*: 2019-11-15
    Sponsor Name:ACADIA Pharmaceuticals Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE 2)
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Completed) HU (Completed) BG (Completed) ES (Ongoing) LT (Completed) IT (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2010-023396-25 Sponsor Protocol Number: SM101-201-sle-10 Start Date*: 2011-09-22
    Sponsor Name:SuppreMol GmbH
    Full Title: Phase IIa, 2:2:1 randomised, double-blind, placebo-controlled, parallel group, multi-centre clinical trial to investigate the safety, efficacy and pharmacokinetics of recombinant human soluble F...
    Medical condition: Systemic lupus erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) CZ (Completed) PL (Completed) NL (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000826-24 Sponsor Protocol Number: INCMGA0012-303 Start Date*: 2020-10-29
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carc...
    Medical condition: Male and female participants at least 18 years of age who have inoperable locally recurrent or metastatic Squamous Carcinoma of the Anal Canal (SCAC) not previously treated with systemic chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10002127 Anal canal cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) GB (GB - no longer in EU/EEA) NO (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) DK (Trial now transitioned) IT (Trial now transitioned) SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-001551-13 Sponsor Protocol Number: D0818C00001 Start Date*: 2013-08-21
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following ...
    Medical condition: BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-000312-24 Sponsor Protocol Number: BGB-A317-305 Start Date*: 2019-04-19
    Sponsor Name:BeiGene, Ltd
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) plus Platinum and Fluoropyrimidine Versus Placebo plus Platinum a...
    Medical condition: Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001158 Adenocarcinoma gastric stage IV with metastases LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) ES (Completed) GB (GB - no longer in EU/EEA) FR (Completed) IT (Completed) RO (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-005387-22 Sponsor Protocol Number: ACP-103-069 Start Date*: 2022-06-27
    Sponsor Name:Acadia Pharmaceuticals Inc.
    Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder
    Medical condition: Treatment of irritability associated with autistic disorder in children and adolescents with ASD
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10063844 Autism spectrum disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Completed) HU (Completed) PL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-014269-25 Sponsor Protocol Number: A0081096 Start Date*: 2009-12-18
    Sponsor Name:Pfizer Inc
    Full Title: PROSPECTIVE RANDOMIZED 12-WEEK CONTROLLED STUDY OF VISUAL FIELD CHANGE IN SUBJECTS WITH PARTIAL SEIZURES RECEIVING PREGABALIN OR PLACEBO
    Medical condition: EPILEPSY WITH PARTIAL SEIZURE
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004852 10065336 Partial epilepsy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2013-001997-18 Sponsor Protocol Number: ACHN-490-007 Start Date*: 2014-02-25
    Sponsor Name:Achaogen, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Plazomicin Compared with Colistin in Patients with Infection due to Carbapenem-Resistant Enterobacteriace...
    Medical condition: Bloodstream infections (BSI) and nosocomial pneumonia due to carbapenem-resistant Enterobacteriaceae (CRE)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10018657 Gram-negative bacterial infection NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) ES (Prematurely Ended) IT (Completed) DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-002025-19 Sponsor Protocol Number: RPC01-2201 Start Date*: 2015-12-30
    Sponsor Name:Celgene International II Sarl (CISII) awholly owned subsidiary of Celgene Corporation
    Full Title: A Phase 2, Multi-Center, Open-Label Induction Trial with Extension Period to Assess Endoscopic Improvement and Changes in Intestinal and Serum Biomarkers in Patients with Moderately to Severely Act...
    Medical condition: Moderately to Severely Active Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10058815 Crohn's disease acute episode LLT
    20.0 100000004856 10011402 Crohn's disease (colon) LLT
    20.0 100000004856 10011403 Crohn's disease aggravated LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-002618-11 Sponsor Protocol Number: I8F-MC-GPGM Start Date*: 2019-05-06
    Sponsor Name:Eli Lilly and Company
    Full Title: Efficacy and Safety of LY3298176 Once Weekly versus Insulin Glargine in Patients with Type 2 Diabetes and Increased Cardiovascular Risk
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) ES (Completed) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2016-001518-39 Sponsor Protocol Number: K-877-303 Start Date*: 2017-01-16
    Sponsor Name:Kowa Research Institute, Inc.
    Full Title: A Phase 3, Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study With a 40-Week, Active-Controlled, Open-Label Extension to Evaluate the Efficacy and Safety of K-877 in Adult Pa...
    Medical condition: Severe hypertriglyceridemia [fasting TG levels >=500 mg/dL (5.65 mmol/L) and <2000 mg/dL (22.60 mmol/L) and mild or moderate renal impairment.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10020667 Hyperlipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed) BG (Completed) CZ (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 230  231  232  233  234  235  236  237  238  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 08:43:40 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA